<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-0289</journal-id>
<journal-title><![CDATA[Revista Cubana de Hematología, Inmunología y Hemoterapia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Hematol Inmunol Hemoter]]></abbrev-journal-title>
<issn>0864-0289</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-02892021000300007</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Eventos adversos a medicamentos durante el tratamiento de inducción de la leucemia linfoide aguda en niños]]></article-title>
<article-title xml:lang="en"><![CDATA[Adverse drug events during the induction treatment of acute lymphoblastic leukemia in children]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gil Agramonte]]></surname>
<given-names><![CDATA[Mildrey]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Year Alós]]></surname>
<given-names><![CDATA[Isis Belkis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González Otero]]></surname>
<given-names><![CDATA[Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Hematología e Inmunología  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro de Ingeniería Genética y Biotecnología  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<volume>37</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-02892021000300007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-02892021000300007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-02892021000300007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  Durante el tratamiento de inducción de la leucemia linfoide aguda en niños no siempre se identifican las reacciones adversas a medicamentos.  Objetivo:  Describir los eventos adversos y las reacciones adversas a medicamentos durante el tratamiento de inducción de la leucemia linfoide aguda, en niños tratados en el Instituto de Hematología e Inmunología de Cuba, durante 2012-2017.  Método:  Estudio observacional, descriptivo, transversal, de series de casos en farmacovigilancia, se utilizó la farmacovigilancia activa. Variables: sexo, edad, grupo pronóstico, semana de tratamiento, tipo de evento adverso, sistema de órgano afectado, severidad e imputabilidad. La información se obtuvo del registro nacional del protocolo ALLIC-BFM 2009 y las historias clínicas.  Resultados: Se incluyeron 69 niños, 55,1 % (38 casos) fueron masculinos, 56,5 % (39 niños) tenía entre uno y seis años. El 52,2 % (36 pacientes) pertenecían al grupo pronóstico intermedio. Se registraron 471 eventos adversos. El 50,5 % (238/471) ocurrió en la primera semana de tratamiento. Los más frecuentes: anemia (17,8 %; 84/471), neutropenia (16,1 %; 76/471) y trombocitopenia (15,9 %; 75/471). Los sistemas de órganos más afectados: hemolinfopoyético (57,54 %; 271/471) y gastrointestinal (15,71 %; 74/471). El 93,2 % (439/471) se clasificó en reacciones adversas posibles. Según gravedad el 72,4 % (330/456) fueron moderadas y el 27,4 % (125/456) graves.  Conclusiones:  Todos los casos presentaron eventos adversos, predominaron las alteraciones hematológicas y los eventos reportados para fármacos incluidos en la quimioterapia. Se identificaron reacciones adversas clasificadas como posibles, con predominio de las moderadas y graves.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  During the induction treatment of acute lymphoid leukemia in children, adverse drug reactions are not always identified.  Aims:  Describe the demographic and clinical characteristics of children with acute lymphoid leukemia who receive induction treatment at the Institute of Hematology and Immunology between 2012-2017. Characterize adverse events that occur during induction treatment. Describe adverse drug reactions during induction.  Methods: Observational, descriptive, cross-sectional study of case series in pharmacovigilance, used active pharmacovigilance. Variables: sex, age, prognosis group, week of treatment, type of adverse event, organ system affected, severity and imputability. The information was obtained from the national register of the ALLIC-BFM 2009 protocol and the medical records.  Results: 69 children were included, 55.1% belonged to the male sex, 56.5% were between one and six years old. 52.2% (36 children) belonged to the intermediate prognosis group. 471 events were recorded. 50.5% occurred in the first week of treatment. The most frequent: anemia (17.8%), neutropenia (16.1%) and thrombocytopenia (15.9%). The most affected organ systems: hemolinfopoietic (57.5%) and gastrointestinal (15.7%). According to the severity, 72.4% were moderate and 27.4% severe.  Conclusions:  The whole presented adverse events, hematological alterations and reported events for drugs included in chemotherapy predominated. Adverse reactions classified as possible were identified, moderate and severe predominated]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[farmacovigilancia]]></kwd>
<kwd lng="es"><![CDATA[leucemia linfoide aguda]]></kwd>
<kwd lng="es"><![CDATA[reacciones adversas]]></kwd>
<kwd lng="es"><![CDATA[hematología]]></kwd>
<kwd lng="en"><![CDATA[pharmacovigilance]]></kwd>
<kwd lng="en"><![CDATA[acute lymphoid leukemia]]></kwd>
<kwd lng="en"><![CDATA[adverse reactions]]></kwd>
<kwd lng="en"><![CDATA[hematology]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="confpro">
<source><![CDATA[Clinical safety data management: definitions and standards for expedited reporting.E2A]]></source>
<year>1994</year>
<conf-name><![CDATA[ International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use]]></conf-name>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hunger]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Mullighan]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute Lymphoblastic Leukemia in Children]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>373</volume>
<page-range>1541-52</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oskarsson]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Söderhäll]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Arvidson]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Forestier]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[LethFrandsen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hellebostad]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia]]></article-title>
<source><![CDATA[Pediatr Blood Cancer]]></source>
<year>2018</year>
<volume>65</volume>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inaba]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current therapeutic approaches in pediatric acute lymphoblastic leukemia]]></article-title>
<source><![CDATA[HematolMéx]]></source>
<year>2018</year>
<volume>19</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>91-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lassaletta Atienza]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Leucemias Leucemia linfoblástica aguda]]></article-title>
<source><![CDATA[Pediatr Integral]]></source>
<year>2016</year>
<numero>6</numero>
<issue>6</issue>
<page-range>380-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González Otero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Menéndez Veitía]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Machín García]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Svarch]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Campo Díaz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández Nodarse]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resultados del tratamiento de la Leucemia Linfoide Aguda del niño en Cuba]]></article-title>
<source><![CDATA[Revista Cubana de Hematol, Inmunol y Hemoter]]></source>
<year>2014</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>36-46</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<source><![CDATA[The WHO Adverse Reaction Terminology- WHO-ART]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karch]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lasagna]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Toward the operational identification of adverse drug reactions]]></article-title>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>1977</year>
<volume>21</volume>
<page-range>247-54</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machín García]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[González Otero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Querol Betancourt]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Escalona Vives]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[García Caraballoso]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández Nodarse]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización y expectativa de vida de las leucemias en edad pediátrica en Cuba. 2006-2015]]></article-title>
<source><![CDATA[Rev Cubana Hematol Inmunol Hemoter]]></source>
<year>2018</year>
<volume>33</volume>
<numero>S1</numero>
<issue>S1</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villalba Toquica]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Silva]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Acero]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización clínico-epidemiológica de los pacientes pediátricos con leucemias agudas en la Clínica Universitaria Colombia. Serie de casos 2011-2014]]></article-title>
<source><![CDATA[Pediatría]]></source>
<year>2016</year>
<volume>49</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>17-22</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stary]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmermann]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Campbell]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Castillo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Dibar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Donska]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intensive Chemotherapy for Childhood Acute Lymphoblastic Leukemia Results of the Randomized Intercontinental Trial ALL IC-BFM 2002]]></article-title>
<source><![CDATA[J ClinOncol]]></source>
<year>2013</year>
<volume>32</volume>
<page-range>174-84</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González Otero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Arencibia Núñez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Machín García]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Menéndez Veitía]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez Díaz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nordet Carrera]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Protocolo ALLIC-BFM 2002 en el Instituto de Hematología e Inmunología: experiencia de 10 años]]></article-title>
<source><![CDATA[Rev Cubana HematolInmunolHemoter]]></source>
<year>2016</year>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>70-85</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jin]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[An]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A review of risk factors for childhood leukemia]]></article-title>
<source><![CDATA[Eur Rev Med Pharmacol Sci]]></source>
<year>2016</year>
<volume>20</volume>
<page-range>3760-4</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pieters]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Groot-Kruseman]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Van der Velden]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Fiocco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Van den Berg]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[de Bont]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring Study ALL10 from the Dutch Childhood Oncology Group]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2016</year>
<volume>34</volume>
<page-range>2591-601</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CananÖzdemir]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[DüzenliKar]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[BozkurtTurhan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bör]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of Hematological Toxicity in Children with Acute Lymphoblastic Leukemia, Receiving Treatment with ALL IC-BFM 2009 Protocol]]></article-title>
<source><![CDATA[OALib J]]></source>
<year>2017</year>
<volume>4</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferreiro]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Barceló]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rubio]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quimioterapia efectos secundarios]]></article-title>
<source><![CDATA[Gac Med Bilbao]]></source>
<year>2003</year>
<volume>100</volume>
<page-range>69-74</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molinés Honrubia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Leucemias linfoblásticas agudas infantiles Evolución histórica y perspectivas futuras]]></article-title>
<source><![CDATA[BSCP Can Ped]]></source>
<year>2001</year>
<volume>25</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>279-90</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ludwig]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Van Belle]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Barrett-Lee]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Birgegård]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bokemeyer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gascón]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The European Cancer Anemia Survey (ECAS) A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anemia in cancer patients]]></article-title>
<source><![CDATA[Eur J Cancer]]></source>
<year>2004</year>
<volume>40</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>2293-306</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmiegelow]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Mogensen]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Mogensen]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Wolthers]]></surname>
<given-names><![CDATA[BO]]></given-names>
</name>
<name>
<surname><![CDATA[Stoltze]]></surname>
<given-names><![CDATA[UK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy]]></article-title>
<source><![CDATA[F1000Res]]></source>
<year>2017</year>
<volume>6</volume>
<page-range>444</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CananÖzdemir]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[DüzenliKar]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[BozkurtTurhan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bör]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of Hematological Toxicity in Children with Acute Lymphoblastic Leukemia, Receiving Treatment with ALLIC-BFM 2009 Protocol]]></article-title>
<source><![CDATA[OALib J]]></source>
<year>2017</year>
<volume>4</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buendía Bravo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[González Haba Peña]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[García Sánchez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Arrabal Durán]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Fresneda]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Sanjurjo Sáez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Análisis descriptivo de los motivos que originan visitas a urgencias en pacientes oncológicos toxicidad postquimioterapia]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2015</year>
<volume>39</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>333-7</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz-Morales]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes-Arvizu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Morgado-Nájera]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Everardo-Domínguez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síntomas en niños con cáncer y estrategias de cuidado familiar]]></article-title>
<source><![CDATA[Rev Cuid]]></source>
<year>2019</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cihan]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Karabulut]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
<name>
<surname><![CDATA[Kutlay]]></surname>
<given-names><![CDATA[NY]]></given-names>
</name>
<name>
<surname><![CDATA[Ruhi]]></surname>
<given-names><![CDATA[HI]]></given-names>
</name>
<name>
<surname><![CDATA[Tükün]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Olcay]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association Between N363S and BclI Polymorphisms of the Glucocorticoid Receptor Gene (NR3C1) and Glucocorticoid Side Effects During Childhood Acute Lymphoblastic Leukemia Treatment]]></article-title>
<source><![CDATA[Turk J Hematol]]></source>
<year>2017</year>
<volume>34</volume>
<page-range>151-8</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fuentes]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Flores]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Iglesias]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Luzuriaga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rendón]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ordoñez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características de la leucemia linfoblástica aguda y neutropenia febril en niños y adolescentes atendidos en un hospital de Guayaquil, Ecuador]]></article-title>
<source><![CDATA[Rev Peru Med Exp Salud Pública]]></source>
<year>2018</year>
<volume>35</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>272-8</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[YB]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[ZG]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Qin]]></surname>
<given-names><![CDATA[MQ]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infections During Induction Therapy of Protocol CCLG-2008 in Childhood Acute Lymphoblastic Leukemia A Single-center Experience with 256 Cases in China]]></article-title>
<source><![CDATA[Chinese Med J]]></source>
<year>2015</year>
<volume>128</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>472-6</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inaba]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Pei]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wolf]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Howard]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Hayden]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Go]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infection-related complications during treatment for childhood acute lymphoblastic leukemia]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2017</year>
<volume>28</volume>
<page-range>386-92</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[León Barrios]]></surname>
<given-names><![CDATA[YR]]></given-names>
</name>
<name>
<surname><![CDATA[Céspedes Quevedo]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Vinent Céspedes]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neutropenia inducida por citostáticos en oncología]]></article-title>
<source><![CDATA[MEDISAN]]></source>
<year>2017</year>
<volume>21</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>3163-71</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendo Alcolea]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Cala Calviño]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Leyva Miranda]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez Escalante]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Traba Delis]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reacciones adversas medicamentosas en pacientes con cáncer atendidos en el Hospital Oncológico Docente "ConradoBenítez"]]></article-title>
<source><![CDATA[MEDISAN]]></source>
<year>2017</year>
<volume>21</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>3145</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palomo-Colli]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Soltero-Becerril]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Juárez Villegas]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Cicero-Oneto]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gaytán-Morales]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Castorena-Villa]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mucositis oral en niños con cáncer y su relación con limitación de actividades]]></article-title>
<source><![CDATA[Gac Mex Oncol]]></source>
<year>2018</year>
<volume>17</volume>
<page-range>87-92</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Juárez-López]]></surname>
<given-names><![CDATA[MLA]]></given-names>
</name>
<name>
<surname><![CDATA[Solano-Silva]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Fragoso-Ríos]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Murrieta-Pruneda]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral diseases in children with acute lymphoblastic leukemia with chemotherapy treatment]]></article-title>
<source><![CDATA[Rev Med Inst Mex Seguro Soc]]></source>
<year>2018</year>
<volume>56</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>132-5</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmiegelow]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Mogensen]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Mogensen]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Wolthers]]></surname>
<given-names><![CDATA[BO]]></given-names>
</name>
<name>
<surname><![CDATA[Stoltze]]></surname>
<given-names><![CDATA[UK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy]]></article-title>
<source><![CDATA[F1000Res]]></source>
<year>2017</year>
<volume>6</volume>
<page-range>444</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alfonso]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Calvo]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Cires]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[Formulario Nacional de Medicamentos]]></source>
<year>2014</year>
<edition>4ta</edition>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Ciencias Médicas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="book">
<source><![CDATA[Martindale Guía Completa de Consulta Farmacoterapéutica]]></source>
<year>2008</year>
<edition>3</edition>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Pharma Editores]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jun]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[YR]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[KG]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy]]></article-title>
<source><![CDATA[BMC Infect Dis]]></source>
<year>2014</year>
<volume>14</volume>
<page-range>161</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Teachey]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[O'Connor]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2020</year>
<volume>135</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>159-66</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maaz]]></surname>
<given-names><![CDATA[AUR]]></given-names>
</name>
<name>
<surname><![CDATA[Badar]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nassir]]></surname>
<given-names><![CDATA[IJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High infection related mortality in pakistani children with acute lymphoblastic leukaemia during remission induction chemotherapy review of data from a single institution]]></article-title>
<source><![CDATA[J Cancer Allied Spec]]></source>
<year>2016</year>
<volume>2</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>6</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
